Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

4D Molecular Therapeutics (FDMT) Share-based Compensation: 2019-2024

Historic Share-based Compensation for 4D Molecular Therapeutics (FDMT) over the last 6 years, with Dec 2024 value amounting to $26.1 million.

  • 4D Molecular Therapeutics' Share-based Compensation fell 30.37% to $4.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $24.0 million, marking a year-over-year decrease of 1.67%. This contributed to the annual value of $26.1 million for FY2024, which is 32.80% up from last year.
  • As of FY2024, 4D Molecular Therapeutics' Share-based Compensation stood at $26.1 million, which was up 32.80% from $19.7 million recorded in FY2023.
  • In the past 5 years, 4D Molecular Therapeutics' Share-based Compensation registered a high of $26.1 million during FY2024, and its lowest value of $5.0 million during FY2020.
  • Moreover, its 3-year median value for Share-based Compensation was $19.7 million (2023), whereas its average is $21.0 million.
  • Data for 4D Molecular Therapeutics' Share-based Compensation shows a peak YoY spiked of 176.87% (in 2021) over the last 5 years.
  • Yearly analysis of 5 years shows 4D Molecular Therapeutics' Share-based Compensation stood at $5.0 million in 2020, then soared by 176.87% to $13.8 million in 2021, then climbed by 24.07% to $17.1 million in 2022, then grew by 14.86% to $19.7 million in 2023, then spiked by 32.80% to $26.1 million in 2024.